Skip to main content
. 2016 Aug 31;36(4):e00374. doi: 10.1042/BSR20160199

Figure 6. Effects of the p38MAPK inhibitor SB203580 treatment on the p27 phosphorylated level and human PASMCs growth.

Figure 6

Treated the human PASMCs with PDGF-BB for 3 h and following pretreatment with NBL1 and/or SB203580. (A) Western blots analysis using phosphor-specific antibodies and co-IP assay (cyclin D1–CDK4 activity). (B) Densitometric analysis of western blotting as shown in (A) lower. GAPDH was used as the loading protein. Treated the human PASMCs with PDGF-BB for 24 h and following pretreatment with NBL1 and/or SB203580. (C) MTS assay (cell proliferation). (D) EdU uptake analysis (cellular DNA synthesis). Data represent as mean ± S.E.M. (N=3). (A and B) *P<0.05, **P<0.01, compared with control, ##P<0.01, compared with PDGF-BB treatment. (C and D) **P<0.01, compared with control, △△P<0.01, compared with PDGF-BB-treated cells.